We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Figure 1

Figure 1. From: Temozolomide as Second or Third Line Treatment of Patients with Neuroendocrine Carcinomas.

Kaplan-Meier survival curves for patients with Ki-67 index <50% versus ≥50%.

Ingrid H. Olsen, et al. ScientificWorldJournal. 2012;2012:170496.

Supplemental Content

Filter your results:

Search details

See more...

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk